Boston Scientific subsidiaries

EndoChoice is a medtech company focused on the manufacturing and commercialization of platform technologies including devices, diagnostics, infection control and endoscopic imaging for specialists treating a wide range of gastrointestinal (GI) diseases. EndoChoice leverages its direct sales organization to serve more than 2,000 customers in the United States and works with 34 distribution partners world-wide. The Company was founded in 2008 and has rapidly developed a proprietary product portfolio, which includes the revolutionary Full Spectrum Endoscopy™ System (Fuse™). The Fuse System is comprised of colonoscopes and gastroscopes with multiple imagers so doctors can see more of the GI tract for diagnosis and treatment. The Fuse colonoscope provides a field of view of 330 degrees versus 170 degrees from traditional endoscopes. In clinical studies, Fuse found 70% more polyps than traditional colonoscopies. 2013 marked the fourth consecutive year EndoChoice was recognized as one of the fastest growing companies in the U.S. by Inc. Magazine. To learn more, visit www.endochoice.com

Cosman Medical offers a comprehensive range of radiofrequency (RF) generators, electrodes, and cannulae for neurosurgery and pain management in interventional anesthesiology and podiatry. Radiofrequency (RF) nerve ablation is a versatile medical technology with a 60-year track record in medicine. It can be used to treat chronic back and neck pain, including pain from facet joint dysfunction, lumbago, sciatica, nerve impingement, intervertebral disc dysfunction, sacroiliac joint dysfunction, headaches, postoperative pain, complex regional pain syndrome (CRPS), reflex sympathetic dystrophy (RSD). It can also be used to treat severe, intractable pain such as that arising from end-stage cancer (cordotomy), nerve root avulsion injury (DREZ and DREZ nucleus caudalis), and trigeminal neuralgia (PSR). In podiatry, RF is used to treat intractable pain from foot, heel, and ankle disorders like plantar fasciitis and Morton's Neuroma. In functional neurosurgery, RF can be used to treat movement disorders such as Parkinson's Disease, essential tremor, and spasticity.

Synecor evolved from the confluence of several synergistic strategic relationships, initially in the field of interventional cardiology, but has expanded its field to include all medical specialties such as obesity, spine therapeutics, and more. Synecor was founded by Dr. Richard Stack after two decades of collaboration with leading cardiologists, clinician-inventors, and scientists from across the nation and as an outgrowth of close working relationships among corporate leaders in the medical device industry, and experts at Duke University. Mr. William Starling, a well-known Silicon Valley medical device entrepreneur/executive with a successful 27-year career in the high technology cardiovascular device industry, partnered with Dr. Stack to co-manage Synecor and form strategic relationships with leading venture capital partnerships (Delphi Ventures and Frazier & Company) and a leading investment bank (Deutsche Banc Alex. Brown). To complete the partner team, Dr. Stack and Mr. Starling also partnered with major life sciences corporations with vast resources and knowledge (Guidant and GE Medical Systems).

Cameron Health, Inc., a development stage medical device company, is creating the next generation of implantable electronic device utilizing state-of-the-art technologies. They are a team of specialized, high technology, creative individuals with decades of experience in solving difficult medical problems. Their current target is the development of a family of devices that will afford patient treatment that has been, until now, unattainable with the current therapeutic modalities and technologies.

Atritech is a private company located in Minneapolis, Minnesota. The company was founded in 2000 and has developed proprietary technology focused on replacing long term anticoagulation therapy for patients with non-valvular atrial fibrillation at risk of stroke. The first implants of the WATCHMAN Left Atrial Appendage Closure Technology were performed in Germany in August of 2002 and in the United States in October of 2003. Since then the company has conducted a large randomized clinical trial comparing the WATCHMAN Left Atrial Appendage Closure Technology to long term Warfarin therapy in patients with non-valvular atrial fibrillation at risk of stroke. The WATCHMAN Device is CE Marked and available in many markets outside the United States. The WATCHMAN Device is currently available For Investigational Use Only in the United States.